

CLAIMS

WHAT IS CLAIMED IS:

- 1 1. An antibody that competitively inhibits binding of SLC15A2
2 polypeptide to a second antibody comprising a CDR sequence of PDO5 #810 or #811.
- 1 2. The antibody of claim 1, wherein the antibody is conjugated to an
2 effector component.
- 1 3. The antibody of claim 2, wherein the effector component is a
2 fluorescent label.
- 1 4. The antibody of claim 2, wherein the effector component is a
2 radioisotope or a cytotoxic chemical.
- 1 5. The antibody of claim 4, wherein the cytotoxic chemical is auristatin.
- 1 6. The antibody of claim 1, wherein the antibody is an antibody fragment.
- 1 7. The antibody of claim 1, wherein the antibody is humanized.
- 1 8. The antibody of claim 1, wherein the antibody comprises an amino
2 acid sequence selected from the group consisting of SEQ ID NO: 7, 8, 9 and 10.
- 1 9. The antibody of claim 1, wherein the SLC15A2 polypeptide is on a
2 cancer or fibrosis cell.
- 1 10. A pharmaceutical composition comprising a pharmaceutically
2 acceptable excipient and the antibody of claim 1.
- 1 11. The pharmaceutical composition of claim 10, wherein the antibody is
2 conjugated to an effector component.
- 1 12. The pharmaceutical composition of claim 11, wherein the effector
2 component is a fluorescent label.
- 1 13. The pharmaceutical composition of claim 11, wherein the effector
2 component is a radioisotope or a cytotoxic chemical.
- 1 14. The pharmaceutical composition of claim 13, wherein the cytotoxic
2 chemical is auristatin.

1 15. The pharmaceutical composition of claim 10, wherein the antibody is
2 humanized.

1 16. The pharmaceutical composition of claim 10, wherein the antibody
2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 8, 9
3 and 10.

1 17. A method of detecting a cancer or fibrosis cell in a biological sample
2 from a patient, the method comprising contacting the biological sample with an antibody of
3 claim 1.

1 18. The method of claim 17, wherein the cancer or fibrosis cell is selected
2 from the group consisting of an ovarian, uterine, prostate, lung, glioblastoma, cervical, or
3 fibrosis-associated cell.

1 19. The method of claim 17, wherein the antibody is conjugated to a
2 fluorescent label.

1 20. A method of inhibiting proliferation of an ovarian, uterine, prostate,
2 lung, glioblastoma, cervical, or fibrosis-associated cell, the method comprising the step of
3 contacting the cell with an antibody of claim 1.

1 21. The method of claim 20, wherein the antibody is an antibody fragment.

1 22. The method of claim 20, wherein the ovarian, uterine, prostate, lung,
2 brain, cervical, or fibrosis cell is in a patient.

1 23. The method of claim 22, wherein the patient is a primate.

1 24. The method of claim 22, wherein the patient is undergoing a
2 therapeutic regimen to treat metastatic ovarian cancer, uterine cancer, prostate cancer, lung
3 cancer, or cervical cancer.

1 25. The method of claim 22, wherein the patient is suspected of having
2 metastatic ovarian cancer, uterine cancer, prostate cancer, lung cancer, or cervical cancer.

1 26. An antibody comprising an amino acid sequence selected from the
2 group of CDR sequences in SEQ ID NO: 7-10.

1 27. The antibody of claim 26, wherein the antibody is conjugated to an
2 effector component.

1 28. A pharmaceutical composition comprising a pharmaceutically
2 acceptable excipient and the antibody of claim 26.

1 29. A method of detecting a cancer or fibrosis cell in a biological sample
2 from a patient, the method comprising contacting the biological sample with an antibody of
3 claim 26.

1 30. A method of inhibiting proliferation of an ovarian, prostate, lung, or
2 cervical cancer or fibrosis-associated cell, the method comprising the step of contacting the
3 cell with an antibody of claim 26.

1